• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Baxter BioPharma Solutions

    Almac Group

    Emergent BioSolutions

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Adare Pharma Solutions

    Emergent BioSolutions

    Syngene

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    10 Bristol-Myers Squibb

    ...

    10 Bristol-Myers Squibb
    On March 5, 2020, BMS unveiled its new corporate brand.
    Kristin Brooks, Managing Editor, Contract Pharma07.15.20
    Headquarters: New York, NY
    twitter.com/bmsnews
    www.bms.com


    Headcount: 30,000
    Year Established: 1887
    Revenues:  $26,145  (+16%)
    Net Income:  $3,460  (-30%)
    R&D:  $6,148  (-3%)

    TOP SELLING DRUGS  
    Drug Indication 2019 Sales (+/-%)
    Eliquis deep vein thrombosis and pulmonary embolism $7,929 23%
    Opdivo melanoma, lung cancer, renal cancer  $7,204  7%
    Sprycel leukemia  $2,110 5%
    Orencia SC rheumatoid arthritis $1,523 10%
    Yervoy  oncology $1,489 12%
    Orencia  rheumatoid arthritis $1,454 9%
    Revlimid Myelodysplastic syndrome (MDS) $1,299 n/a
    Baraclude hepatitis B $555  -25%
    Empliciti  multiple myeloma $357 45%


    Bristol-Myers-Squibb (BMS) rounds out this year’s Top 10. In the first quarter of 2020 revenues soared 82% to $10.8 billion, supercharged by the impact of the Celgene acquisition completed in November, and representing 71% of the growth, namely from its flagship products Revlimid, Pomalyst/Imnovid, and Abraxane. BMS also saw several significant clinical and regulatory milestones across its portfolio.

    In one fell swoop, the $74 billion acquisition of Celgene created leading oncology franchises in both solid tumors and hematologic malignancies with Opdivo and Yervoy as well as Revlimid and Pomalyst; a top five immunology and inflammation franchise with Orencia and Otezla; and the number one cardiovascular franchise led by Eliquis. The combined company has nine products with more than $1 billion in annual sales and is seeing growth in the core disease areas of oncology, immunology and inflammation and cardiovascular disease.

    Of the near-term launch opportunities from the Celegene acquisition, Zeposia (ozanimod) won approval in relapsing remitting multiple sclerosis (RRMS), and Reblozyl (luspatercept) for the treatment of anemia. BMS recently received a Refusal to File letter from the FDA regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, citing further CMC detail is needed to complete the review. BMS plans to resubmit no later than the end of July 2020. Finally, the BLA for liso-cel in relapsed or refractory large B-cell lymphoma is currently under priority review, with an FDA target action date of August 17, 2020.

    In line with strategic efforts to simplify and to realign its business portfolio, the company completed the divestment of its consumer health business, UPSA, to Taisho Pharmaceutical Co., for $1.6 billion, to help address changes in its business and the future requirements of its evolving pipeline. Also, in August, Celgene, in connection with its merger agreement with BMS, entered into an agreement to sell the global rights to OTEZLA to Amgen for $13.4 billion, providing additional funds for strategic efforts.

    Pipeline progress
    Top sellers, Opdivo plus Yervoy recently picked up three additional indication approvals by the FDA, one for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor abnormalities, which demonstrated superior overall survival versus chemotherapy regardless of PD-L1 expression or tumor histology; and another for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1. Additionally, the FDA accelerated approval of the therapy for patients with Hepatocellular Carcinoma (HCC) previously treated with Sorafenib, marking the sixth indication for the therapy.

    Also, a partnership with Bayer and Ono Pharmaceutical Co. is evaluating the combination of Bayer's kinase inhibitor Stivarga (regorafenib) and Opdivo in micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC. Recent results from the Phase Ib REGONIVO trial demonstrated promising antitumor activity and tolerability in patients with gastric and colorectal cancer (CRC).

    The recent approval of Zeposia in the U.S. and Europe for the treatment of RRMS, marked the first approvals resulting from the Celgene acquisition. ZEPOSIA demonstrated efficacy on a key clinical marker of disease activity, annualized relapse rate, as compared to Biogen’s Avonex, which had sales of $1.7 billion in 2019, a decline of 13%. However, Zeposia offers RRMS patients a new oral option to help address the disease's hallmark relapses and brain lesions. It’s currently the only approved sphingosine-1-phosphate (S1P) receptor modulator for RRMS.

    While Zeposia enters a crowded MS market, the drug recently met primary endpoints in a Phase III trial as an induction and maintenance therapy for moderate to severe ulcerative colitis, demonstrating highly statistically significant results for clinical remission and in maintenance. The study also met key secondary endpoints of clinical response and endoscopic improvement. BMS is also investigating Zeposia for the treatment of moderately to severely active Crohn's disease in the ongoing Phase III YELLOWSTONE clinical trial program.

    Additionally, in April, the FDA approved Reblozyl, becoming the first and only erythroid maturation agent (EMA), for the treatment of anemia, failing an erythropoiesis stimulating agent. The FDA approval marks the second indication for Reblozyl and the first new treatment option in over a decade for patients with myelodysplastic syndromes (MDS) who require red blood cell (RBC) transfusions. Reblozyl works by regulating late-stage RBC maturation to relieve patients from the burden of regular RBC transfusions.

    Another win for Celgene’s flagship Revlimid, which had sales of $10.8 billion in 2019, a new indication in combination with rituximab (anti-CD20 antibody) for the treatment of adults with previously treated follicular lymphoma (FL), makes it the first chemotherapy-free combination regimen approved for patients with FL by the European Commission. Clinical trials touted statistically significant improvements in progression-free survival.

    Also, Celgene’s second highest selling drug, Pomalyst, gained FDA approval for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative.

    As mentioned above, BMS anticipates approval of idecabtagene vicleucel after resubmission in the U.S., as well as approval from the European Medicines Agency after its Marketing Authorization Application was recently validated. The companies' lead investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with multiple myeloma who have received at least three prior therapies, met the primary and secondary endpoints of overall response rate and complete response rate, respectively, in KarMMa trials.

    Additionally, results from a TRANSCEND trial evaluating liso-cel in relapsed/refractory large B-cell lymphomas, met its primary and secondary end points, with overall response rate of 73%, and, of the patients who responded to liso-cel, 53% achieved a complete response. The median progression-free survival was 6.8 months, and median overall survival was an impressive 21.1 months.
    With several portfolio advances and the strength of BMS’ prioritized brands, Revlimid, Opdivo, and Eliquis, we can anticipate BMS’ continued rise in the rankings in the next few years. 

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20


    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 04 Johnson & Johnson

      04 Johnson & Johnson

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • ICON Acquires Medpass
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    GUM Recalls Oral Spray
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login